Medistim receives EU MDR certificates for MiraQ systems and TTFM probes

18 Oct 2024 12:53 CEST

(Oslo, October 18, 2024) - Medistim ASA (OSE: MEDI) is a niche market leader in
ultrasound technology, headquartered in Oslo, Norway. The company specializes in
developing and commercializing advanced medical equipment for Cardiac, Vascular,
and Transplant surgeries. Today, the company announced it has received EU
Medical Device Regulation (MDR) certification for its MiraQ™ ultrasound systems
and Transit Time Flow Measurement (TTFM) probes.

After years of preparation, Medistim has successfully obtained its first CE
certificates under the latest EU Medical Device Regulation (EU MDR 2017/745).

This achievement represents a key milestone, affirming Medistim’s compliance
with the most rigorous medical device standards set by the European Union. The
new EU MDR imposes stricter requirements on safety, performance, and
traceability of medical devices, with the goal of enhancing patient protection.
Medistim’s successful certification underscores its dedication to excellence and
its mission to deliver high-impact solutions that make a clinically significant
difference in healthcare worldwide.

“Receiving the CE certificate under the EU MDR for our MiraQ™ system platform is
a testament to the dedication and hard work of our entire team," said Kari E.
Krogstad, President and CEO at Medistim. "This accomplishment reflects our
unwavering commitment to delivering safe and reliable medical devices to our
customers worldwide."

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden and Norway, in addition to around 60 distributors in
Europe, Asia, the Middle East, Africa, and South America.

For more information, visit the Medistim home page: www.medistim.com

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

More information:
Access the news on Oslo Bors NewsWeb site